In our March issue :
FEATURED
Clinical Trials: The Patient Perspective
Lindsey Wahlstrom-Edwards, Anne-Marie Hess
Despite the focus in recent years on how patient centricity can impact clinical trial design, the general consensus is much work remains to realize its potential in this setting. To that end, authors present results of a survey that uncovers deeper learnings of patient perceptions of clinical research and their motivations to participate.
Analyzing Awareness Dynamics
Ken Getz, Ellyn Getz
A look at the current communication environment for public and patient clinical trial awareness and education—and the effectiveness of campaigns put in place by the Center for Information and Study on Clinical Research (CISCRP) to boost awareness and literacy.
The Evolution of Patient Centricity
Moe Alsumidaie
Article chronicles the start and evolution of patient centricity, highlighting the distinct actions and advocacy that have advanced the concept from buzzword status to practical implementation in clinical studies.
PEER-REVIEWED
Site Selection: A Portfolio Approach
Vadim Paluy, MD, Vladimir Shnaydman, PhD
With site selection an often challenging and problematic task in clinical trial planning, authors explore the merits of selecting a portfolio of sites—based on advanced analytical models—to optimize the process.
|
NEWS
Eye on Patient Advocacy: Second column in series details how using a multimodal recruitment plan helped exceed enrollment goals.
Washington Report: Jill Wechsler on FDA's more defined plans for assessing and regulating cellular and gene-based medicines.
EU Report: Peter O'Donnell outlines the EMA's efforts to balance the proliferation of threats and opportunities from big data.
Q&A: Experts share insights on the importance of patient centricity in real-world evidence collection.
|
CLINICAL TRIAL INSIGHTS
Plain Language Transparency
Ken Getz
The time has come to establish standard practices to return clinical trial results summaries—in plain language—to patients.
|
CLOSING THOUGHT
Monetizing Shared Digital Health
Richard Tsai
How the increasing launch of models to enable individuals to own and transact their medical data could propel drug discovery, particularly for rare diseases.
|
|
|
If you would like to submit an article to Applied Clinical Trials, contact Lisa Henderson, Editorial Director - lisa.henderson@ubm.com
Applied Clinical Trials is free to qualified subscribers. To subscribe, click here.
Click here to contact the Applied Clinical Trials sales team. |
